REGENERON PHARMACEUTICALS, INC. Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31)
REGENERON PHARMACEUTICALS, INC. (REGN) had Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) of $460.91 million as of 2012-09-30, per its 10-Q filed 2012-10-24.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost · last filed 2012-10-24
- 2012-09-30: Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) $460.91M.
- 2012-06-30: Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) $422.64M.
- 2012-03-31: Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) $296.68M.
- 2011-12-31: Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) $321.85M.
| Period end | Available-for-sale Securities, Debt Maturities, Amortized Cost Basis (Deprecated 2014-01-31) |
|---|---|
| 2012-09-30 | $460.91M 10-Q · filed 2012-10-24 |
| 2012-06-30 | $422.64M 10-Q · filed 2012-07-25 |
| 2012-03-31 | $296.68M 10-Q · filed 2012-04-26 |
| 2011-12-31 | $321.85M 10-Q · filed 2012-10-24 |
| 2011-09-30 | $300.86M 10-Q · filed 2011-10-27 |
| 2011-06-30 | $309.77M 10-Q · filed 2011-07-28 |
| 2010-12-31 | $511.63M 10-Q · filed 2011-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |